Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Abstract

<div>Abstract<p>Most patients with <i>BRAF</i><sup>V600</sup>-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely understood. We performed whole-exome sequencing on formalin-fixed, paraffin-embedded tumors from 45 patients with <i>BRAF</i><sup>V600</sup>-mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy. Genetic alterations in known or putative RAF inhibitor resistance genes were observed in 23 of 45 patients (51%). Besides previously characterized alterations, we discovered a “long tail” of new mitogen-activated protein kinase (MAPK) pathway alterations (<i>MAP2K2</i>, <i>MITF</i>) that confer RAF inhibitor resistance. In three cases, multiple resistance gene alterations were observed within the same tumor biopsy. Overall, RAF inhibitor therapy leads to diverse clinical genetic resistance mechanisms, mostly involving MAPK pathway reactivation. Novel therapeutic combinations may be needed to achieve durable clinical control of <i>BRAF</i><sup>V600</sup>-mutant melanoma. Integrating clinical genomics with preclinical screens may model subsequent resistance studies.</p><p><b>Significance:</b> The use of RAF inhibitors for <i>BRAF</i><sup>V600</sup>-mutant metastatic melanoma improves patient outcomes, but most patients demonstrate early or acquired resistance to this targeted therapy. We reveal the genetic landscape of clinical resistance mechanisms to RAF inhibitors from patients using whole-exome sequencing, and experimentally assess new observed mechanisms to define potential subsequent treatment strategies. <i>Cancer Discov; 4(1); 94–109. ©2013 AACR</i>.</p><p>See related commentary by Solit and Rosen, p. 27</p><p>This article is highlighted in the In This Issue feature, p. 1</p></div>